Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs

Cancer Science

Volumn 99, Issue 2, 2008, Pages 376-384

  Ozaki, Kei Ichi ^a   Kishikawa, Futaba ^a   Tanaka, Masashi ^a   Sakamoto, Toshiaki ^a   Tanimura, Susumu ^a   Kohno, Michiaki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYTARABINE; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HISTONE; HISTONE DEACETYLASE INHIBITOR; MITOMYCIN C; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PACLITAXEL; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; SERINE; TOPOTECAN; VINCRISTINE;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CHROMATIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG USE; HUMAN; HUMAN CELL; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASES; HUMANS; REACTIVE OXYGEN SPECIES;

EID: 38949146354     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00669.x     Document Type: Article

References (40)

1. Estellaer M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-98.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
3. Nalikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002; 108: 475-87.
4. Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: A dynamic perspective. Mol Cell 2006; 23: 289-96.
5. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20: 615-26.
6. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18: 2315-35.
7. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-53.
8. Marks PA, Rifkind RA, Richon VM et al. Histone deacetylase and cancer: cause and therapies. Nat Rev Cancer 2001; 1: 194-202.
9. Zhu P, Martin E, Mengwasser J et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004; 5: 455-63.
10. Johnstone RW. Histone deacetylase inhibitors: Novel drugs for treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-99.
11. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-68.
12. Insinga A, Monestiroli S, Ronzoni S et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-6.
13. Nebbioso A, Clarke N, Voltz E et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77-84.
14. Ozaki K, Minoda A, Kishikawa F, Kohno M. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochem Biophys Res Commun 2006; 339: 1171-7.
15. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
16. Görisch SM, Wachsmuth M, Tóth KF, Lichter P, Rippe K. Histone acetylation increases chromatin accessibility. J Cell Sci 2005; 118: 5825-34.
17. Camphausen K, Cerna D, Scott T et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005; 114: 380-6.
18. Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 2006; 25: 3885-93.
19. Kim MS, Baek JH, Chakravarty D, Sidransky D, Carrier F. Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA). Exp Cell Res 2005; 306: 94-102.
20. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291-300.
21. Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006; 448: 797-804.
22. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002; 2: 188-200.
23. Hoshino R, Chatani Y, Yamori T et al. Constitutive activation of the 41-/ 43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22.
24. Tanimura S, Nomura K, Ozaki K, Tsujimoto M, Kondo T, Kohno M. Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J Biol Chem 2002; 277: 28256-64.
25. Kip1. J Biol Chem 2001; 276: 2686-92.
26. Fujiwara Y, Kawada K, Takano D, Tanimura S, Ozaki K, Kohno M. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochem Biophys Res Commun 2006; 340: 560-6.
27. Ozaki K, Miyazaki S, Tanimura S, Kohno M. Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J Cell Sci 2005; 118: 5861-71.
28. Fujiwara Y, Hosokawa Y, Watanabe K, Tanimura S, Ozaki K, Kohno M. Blockade of the phosphatidylinositol-3-kinase Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated. Mol Cancer Ther 2007; 6: 1133-42.
29. Schilder RJ, Hall L, Monks A et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990; 45: 416-22.
30. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 1999; 27: 1-20.
31. Diaz C, Lee AT, McConkey DJ, Schroit AJ. Phosphatidylserine externalization during differentiation-triggered apoptosis of erythroleukemic cells. Cell Death Differ 1999; 6: 218-26.
32. Rogakou EP, Pilch DR, Orr AH, Ivanova VH, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-68.
33. Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M. Role of reactive oxygen species in cis-dichlorodiamineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 1997; 76: 206-10.
34. Huang HL, Fang LW, Lu SP, Chou CK, Luh TY, Lai MZ. DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 2003; 22: 8168-77.
35. Pendyala L, Creaven PJ. In vivo cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
36. Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 2001; 21: 6913-26.
37. Ruefli AA, Ausserlechner MJ, Bernhard D et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-8.
38. CIP1/WAF1. Cancer Res 2003; 63: 3637-45.
39. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-42.
40. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlated with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703-8.